The estimated Net Worth of Albertfcmi Parent Co. Fried... is at least $4.43 million dollars as of 9 August 2024. Albertfcmi Fried owns over 100 units of Vaccinex Inc stock worth over $4,426,138 and over the last 6 years Albertfcmi sold VCNX stock worth over $0.
Sign up
Albertfcmi Fried VCNX stock SEC Form 4 insiders trading
Albertfcmi has made over 18 trades of the Vaccinex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Albertfcmi bought 100 units of VCNX stock worth $451 on 9 August 2024.
The largest trade Albertfcmi's ever made was buying 3,603,602 units of Vaccinex Inc stock on 27 January 2022 worth over $3,999,998. On average, Albertfcmi trades about 450,148 units every 82 days since 2019. As of 9 August 2024 Albertfcmi still owns at least 780,624 units of Vaccinex Inc stock.
You can see the complete history of Albertfcmi Fried stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Albertfcmi Fried's mailing address?
Albertfcmi's mailing address filed with the SEC is 220 BAY STREET220 BAY STREET, SUITE 600SUITE 600, TORONTOTORONTO, A6A6, M5J 2W4M5J 2W4.
Insiders trading at Vaccinex Inc
Over the last 6 years, insiders at Vaccinex Inc have traded over $3,161 worth of Vaccinex Inc stock and bought 14,062,785 units worth $29,583,294 . The most active insiders traders include Albertfcmi Parent Co. Fried..., Maurice Zauderer et Maurice Vaccinex (Rochester.... On average, Vaccinex Inc executives and independent directors trade stock every 61 days with the average trade being worth of $2,417,268. The most recent stock trade was executed by Albertfcmi Parent Co. Fried... on 9 August 2024, trading 100 units of VCNX stock currently worth $451.
What does Vaccinex Inc do?
located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
What does Vaccinex Inc's logo look like?
Complete history of Albertfcmi Fried stock trades at Vaccinex Inc
Vaccinex Inc executives and stock owners
Vaccinex Inc executives and other stock owners filed with the SEC include:
-
Dr. Maurice Zauderer Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Ernest S. Smith Ph.D.,
Sr. VP of Research & Chief Scientific Officer -
Scott E. Royer C.F.A., M.B.A.,
Chief Financial Officer -
Dr. John E. Leonard Ph.D.,
Sr. VP of Devel. -
Dr. Elizabeth E. Evans Ph.D.,
COO and Sr. VP of Discovery & Translational Medicine -
Elizabeth E. Evans,
COO and Sr. VP of Discovery & Translational Medicine -
John E. Leonard Ph.D.,
Sr. VP of Devel. -
Dr. Deepak M. Sahasrabudhe,
Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor -
Maurice Vaccinex (Rochester...,
President and CEO -
Jill Sanchez,
Chief Financial Officer -
Albert Vaccinex (Rochester)...,
-
Bala S Manian,
Director -
Jeff Goater,
Director -
Albertfcmi Parent Co. Fried...,
-
Robert Scala,
Chief Commercial Officer -
Jacob B. Frieberg,
Director -
Raymond E. Watkins,
SVP & Chief Operating Officer -
Barbara Yanni,
Director -
Alejandro M. Berlin,
Director -
Inc. Vaccinex,,
Director -
Ernest S. Smith,
SVP, Research & CSO -
John E. Leonard,
SVP, Development -
Scott E. Royer,
Chief Financial Officer -
Strydonck, Gerald E. Van,
Director -
Elizabeth E. Evans,
Chief Operating Officer -
Maurice Zauderer,
President and CEO